All In Biotech

Drug Trial Radar · NCT01175590

Safety of Besivance™ (Besifloxacin Ophthalmic Suspension) 0.6% Compared to Vehicle

A Study to Evaluate the Safety of Besivance™ (Besifloxacin Ophthalmic Suspension) 0.6% Compared to Vehicle Following Three Times Daily(TID) Dosing for 7 Days

Last checked: Nov 20, 2026Latest source record: May 1, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 518 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

518

Actual

Start

Jun 2010

Primary completion

Dec 2011

Study completion Feb 2012

Sponsor

Lead sponsor
Bausch & Lomb IncorporatedIndustry
Sponsor type
Industry
First posted
Aug 5, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 1 year
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this study is to evaluate the safety of Besivance (besifloxacin ophthalmic suspension, 0.6%) compared to vehicle.

Conditions

  • Bacterial Conjunctivitis

Interventions

  • BesivanceDrug

    Ocular administration to affected eye for 7 days

  • VehicleDrug

    Vehicle of Besivance administered to affected eye for 7 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Ocular Treatment Emergent Adverse EventsTime frame: At each visit - 7 days
  2. Non-Ocular Treatment-Emergent Adverse EventsTime frame: 7 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Bausch & Lomb, Inc.

    Rochester, New York

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.